Join us on our journey to
end blood cancer.
We are the only foundation in the world that supports patients with RUNX1-FPD.
Join Our 2025 X-Out Blood Cancer Campaign!
Families with RUNX1-FPD have waited a long time for real progress, and now, for the first time, clinical trials are open that focus specifically on their condition.
This May, we’re raising $50,000 to help patients overcome the biggest barrier to participation: the cost of travel. Your support doesn't just fund research, it gives every family the chance to be part of the future of blood cancer prevention. Join us today! Click below to donate and/or set up your own fundraiser.
Take part in shaping a future where blood cancer doesn’t exist.
What is RUNX1 Familial Platelet Disorder (RUNX1-FPD)?
RUNX1-FPD (also known as RUNX1-FPDMM or FPD-AML) is a rare inherited disease caused by a mutation in the RUNX1 gene, resulting in lower blood platelet counts, platelet dysfunction, and an increased risk of early-onset blood cancers.
Individuals with this disease primarily develop acute myeloid leukemia (AML), the second deadliest blood cancer.
RUNX1-FPD patients often face a range of health issues including asthma, allergies, autoimmune disorders and gastrointestinal problems.
Discovered in 1999, this disease varies greatly between families, even within families, with some having a significantly higher incidence of blood cancer development.
There is a 50% chance for each child to have the RUNX1 mutation, no matter if they are male or female.
